Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in an unprecedented public health crisis. There are no approved vaccines or therapeutics for treating COVID-19. Here we report a humanized monoclonal antibody, H014, t...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Science (American Association for the Advancement of Science) Jg. 369; H. 6510; S. 1505
Hauptverfasser:	Lv, Zhe, Deng, Yong-Qiang, Ye, Qing, Cao, Lei, Sun, Chun-Yun, Fan, Changfa, Huang, Weijin, Sun, Shihui, Sun, Yao, Zhu, Ling, Chen, Qi, Wang, Nan, Nie, Jianhui, Cui, Zhen, Zhu, Dandan, Shaw, Neil, Li, Xiao-Feng, Li, Qianqian, Xie, Liangzhi, Wang, Youchun, Rao, Zihe, Qin, Cheng-Feng, Wang, Xiangxi
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 18.09.2020
Schlagworte:	Angiotensin-Converting Enzyme 2 Animals Antibodies, Monoclonal, Humanized - chemistry Antibodies, Monoclonal, Humanized - therapeutic use Antibodies, Neutralizing - chemistry Antibodies, Neutralizing - therapeutic use Betacoronavirus - immunology Chlorocebus aethiops Coronavirus Infections - therapy COVID-19 Epitope Mapping Humans Immunoglobulin Fab Fragments - chemistry Lung - immunology Mice Pandemics Peptidyl-Dipeptidase A - immunology Pneumonia, Viral - therapy Protein Domains Protein Multimerization Receptors, Virus - immunology SARS Virus - immunology SARS-CoV-2 Vero Cells
ISSN:	1095-9203, 1095-9203
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!